BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32433235)

  • 1. Live Donor Liver Transplantation in the United States: Impact of Share 35 on Live Donor Utilization.
    Braun HJ; Dodge JL; Grab JD; Schwab ME; Liu IH; Glencer AC; Stock PG; Hirose R; Roberts JP; Ascher NL
    Transplantation; 2021 Apr; 105(4):824-831. PubMed ID: 32433235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved retransplant outcomes: early evidence of the share35 impact.
    Brooks JT; Koizumi N; Neglia E; Gdoura B; Wong TW; Kwon C; Smith TE; Ortiz J
    HPB (Oxford); 2018 Jul; 20(7):649-657. PubMed ID: 29500002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low Model for End-Stage Liver Disease Recipients.
    Kling CE; Perkins JD; Reyes JD; Montenovo MI
    Liver Transpl; 2019 Apr; 25(4):580-587. PubMed ID: 29637730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of living-donor liver transplantation in patients with a model for end-stage liver disease over 30 in a region with severe organ shortage: a retrospective cohort study.
    Yim SH; Kim DG; Kang M; Koh HH; Choi MC; Min EK; Lee JG; Kim MS; Joo DJ
    Int J Surg; 2023 Nov; 109(11):3459-3466. PubMed ID: 37565633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in partial liver transplantation: deceased donor split-liver vs. live donor liver transplantation.
    Saidi RF; Jabbour N; Li Y; Shah SA; Bozorgzadeh A
    HPB (Oxford); 2011 Nov; 13(11):797-801. PubMed ID: 21999593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of rates and severity of chronic kidney disease in deceased-donor and living-donor liver transplant recipients: times matter.
    Yankol Y; Bugeaud E; Zens T; Rizzari M; Mecit N; Leverson GE; Foley D; Mezrich JD; Kanmaz T; Andaçoğlu OM; D'Alessandro AM; Acarlı KS; Kalayoğlu M; Fernandez LA
    Turk J Med Sci; 2021 Apr; 51(2):610-622. PubMed ID: 33037873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining long-term outcomes with living donor liver transplantation in North America.
    Olthoff KM; Smith AR; Abecassis M; Baker T; Emond JC; Berg CL; Beil CA; Burton JR; Fisher RA; Freise CE; Gillespie BW; Grant DR; Humar A; Kam I; Merion RM; Pomfret EA; Samstein B; Shaked A
    Ann Surg; 2015 Sep; 262(3):465-75; discussion 473-5. PubMed ID: 26258315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Section 12. Living donor liver transplantation for patients with high model for end-stage liver disease scores and acute liver failure.
    Kaido T; Tomiyama K; Ogawa K; Fujimoto Y; Ito T; Mori A; Uemoto S
    Transplantation; 2014 Apr; 97 Suppl 8():S46-7. PubMed ID: 24849834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National experience with living donor liver transplantation for hepatocellular carcinoma.
    Silverstein J; Yao FY; Grab JD; Braun HJ; Roberts J; Dodge JL; Mehta N
    Liver Transpl; 2022 Jul; 28(7):1144-1157. PubMed ID: 35226793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area.
    Chok KS; Fung JY; Chan AC; Dai WC; Sharr WW; Cheung TT; Chan SC; Lo CM
    Ann Surg; 2017 Jan; 265(1):173-177. PubMed ID: 28009743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Risk of End-Stage Renal Disease Among Living Donor Liver Transplant Recipients in the United States.
    Goldberg DS; Ruebner RL; Abt PL
    Am J Transplant; 2015 Oct; 15(10):2732-8. PubMed ID: 25969133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and Safety of Split-Liver Transplantation in a Nascent Framework of Deceased Donation.
    Cherukuru R; Reddy MS; Shanmugam NP; Rajalingam R; Kota V; Gunasekaran V; Narasimhan G; Kaliamoorthy I; Rela M
    Liver Transpl; 2019 Mar; 25(3):450-458. PubMed ID: 30586233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation.
    Vagefi PA; Ascher NL; Freise CE; Dodge JL; Roberts JP
    Liver Transpl; 2012 Feb; 18(2):160-5. PubMed ID: 22006378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
    Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
    Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in Living Donor Compared With Deceased Donor Primary Liver Transplantation in Lower Acuity Patients With Model for End-Stage Liver Disease Scores <30.
    Kitajima T; Moonka D; Yeddula S; Collins K; Rizzari M; Yoshida A; Abouljoud MS; Nagai S
    Liver Transpl; 2021 Jul; 27(7):971-983. PubMed ID: 33492764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Living Donor Liver Transplantation for Adults With High Model for End-stage Liver Disease Score: The US Experience.
    Rosenthal BE; Abt PL; Schaubel DE; Reddy KR; Bittermann T
    Transplantation; 2024 Mar; 108(3):713-723. PubMed ID: 37635282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
    Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
    Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons Learned From Review of a Single Center Experience With 500 Consecutive Liver Transplants in a Region With Insufficient Deceased-Donor Support.
    Yankol Y; Mecit N; Kanmaz T; Cimsit B; Cakaloglu Y; Acarli K; Kalayoglu M
    Exp Clin Transplant; 2016 Apr; 14(2):191-200. PubMed ID: 26030810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.